Fibromyalgia is a debilitating chronic syndrome characterized by diffuse pain, fatigue, and a wide range of other symptoms. It is not contagious, and recent studies suggest that people with fibromyalgia may be genetically predispose. It affects more women than men, with a ratio globally of 3-5:1. Fibromyalgia is seen in 3-10% of the general population, and is mostly found between the ages 20 and 50.
King Pharmaceuticals Reports FDA Approval Of New Skelaxin Label

Fibromyalgia :: King Pharmaceuticals Reports FDA Approval Of New Skelaxin Label
King Pharmaceuticals (NYSE: KG) reported today that the U.S. Food and Drug Administration (?FDA?) has approved the Company?s revised prescribing information for its Skelaxin? (metaxalone) product. Skelaxin? is a leading branded muscle relaxant, indicated as an adjunct therapy for the relief of discomforts associated with acute, painful musculoskeletal conditions. The new labeling includes revised ?Precautions? and ?Clinical Pharmacology: Pharmacokinetics? sections.
About Skelaxin?
SKELAXIN? is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man. The most frequent reactions to metaxalone include nausea, vomiting, gastrointestinal upset, drowsiness, dizziness, headache, and nervousness or "irritability."
(
Fibromyalgia :: King Pharmaceuticals Reports FDA Approval Of New Skelaxin Label published at
SpiritIndia on Friday, December 8, 2006)